India, Nov. 18 -- Mandos, LLC, a subsidiary of Beren Therapeutics, received U.S Food and Drug Administration (FDA) approval for Lembaz (adrabetadex) on November 17, 2026. It is the first therapy shown to help patients with infantile-onset Niemann-Pick disease type C live

Niemann-Pick disease type C (NPC) is a rare inherited disorder in which the body cannot properly process cholesterol and other fats, leading to their buildup in cells, particularly in the brain. Over time, the disease causes progressive neurological decline, including problems with movement, coordination and swallowing. Patients whose symptoms begin before age six generally experience the most severe form of the disease.

Lembaz is approved for adults and children weighing...